Home > Result Summaries: Compounds > telmisartan Result Summaries: telmisartan GSKStudy ID Phase Title Summary (Download) 105935 Phase 3 A Post-Marketing Surveillance to monitor the safety of PritorPlusTM (telmisartan/hydrochlorothiazide) administered in Korean subjects according to the prescribing information (0 citation(s)) AZA30002 Phase 3 An open, non-controlled study to investigate the safety and efficacy of 12 to 96 weeks of treatment with telmisartan when administered to patients with hypertension. (1 citation(s)) AZA30003 Phase 3 A prospective double-blind, randomised, placebo-controlled, 3 week crossover study to investigate the effects of telmisartan 40mg on arterial compliance and endothelial function in type 2 diabetes subjects with essential hypertension. (1 citation(s)) AZA30004 Phase 3 A prospective, double-blind, randomised, placebo-controlled, 3 week cross-over study to investigate the effects of telmisartan on pulse wave velocity and arterial compliance in subjects with isolated systolic hypertension. (0 citation(s)) AZA30005 Phase 3 A prospective, randomised, open-label, blinded endpoint (PROBE), parallel group study comparing a one-step response based titration regimen of 12 weeks duration of telmisartan with enalapril in patients with essential hypertension. (1 citation(s)) AZA30006 Phase 3 A prospective, randomized, double-blind, parallel group study to compare the adjunctive effect of telmisartan with existing antihypertensive therapy in patients with essential hypertension that is uncontrolled on current therapy. (1 citation(s)) AZA30012 Phase 4 An open label randomized study of efficacy and safety of telmisartan administered during 12 weeks in combination and as sequential single therapy (TEAM study). (0 citation(s)) AZA30013 Phase 4 Comparison, with self measurements of blood pressure, of residual efficacy of telmisartan and perindopril in mild to moderate essential hypertension (EVERESTE study). (1 citation(s)) AZA30015 Phase 3 P.R.O.B.E. (Prospective, Randomized, Open-label, Blinded Endpoint) multicentre, parallel-group study to evaluate the efficacy of telmisartan 40/80 mg vs losartan 50/100 mg in patients with mild/moderate hypertension (0 citation(s)) AZA30016 Phase 3 P.R.O.B.E. (Prospective, Randomized, Open label, Blinded Endpoint) multicentre, parallel group study to evaluate the efficacy of telmisartan 40/80 mg vs lisinopril 10/20 mg in the reduction of progressive renal impairment in hypertensive subjects with type 2 diabetes. (0 citation(s)) AZA30020 Phase 3 Acute effects of the Angiotensin 1 receptor blockade, telmisartan 80 mg, on the nitric oxide flow-mediated vasodilation of radial artery, in healthy volunteers (0 citation(s)) AZA40052; AZA40053 Phase 4 Telmisartan Therapy for Hypertension in a Primary-Care Setting: A Canadian Observational Study (0 citation(s)) HAZ30001 Phase 3 A prospective, randomised, open-label, blinded-endpoint, parallel group study comparing telmisartan plus hydrochlorothiazide with losartan plus hydrochlorothiazide in subjects with essential hypertension. (1 citation(s)) HAZ30002 Phase 3 A prospective, randomised, open-label, parallel group study to investigate the effects of 12 months treatment with telmisartan plus hydrochlorothiazide or ramipril plus hydrochlorothiazide on left ventricular mass index in subjects with left ventricular hypertrophy and essential hypertension (0 citation(s))
